Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae

Chin Te Lu, Yin Ching Chuang, Wu Sun, Yung Ching Liu, Yu Jen Cheng, Po Liang Lu, Chih Ming Chen, Gwo Jong Hsu, Tsrang Neng Jang, Chun Ming Lee, Ping Cherng Chiang, Zhi Yuan Shi, Lih Shinn Wang, Hsiang Chi Kung, Hsiu Chen Lin, Chun Hsing Liao, Jien Wei Liu, Cheng Hua Huang, Shih Ming Tsao, Po Ren Hsueh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria. This study compared the in-vitro activity of tigecycline against clinical isolates of resistant Gram-negative bacteria determined by the broth microdilution and Etest methods. A total of 622 isolates were collected from patients treated at 20 teaching hospitals. Tigecycline had excellent in-vitro activity against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC90 0.5 μg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC90 2 μg/mL and a 98.5% susceptibility rate. For ESBL-producing Proteus mirabilis (N = 15) the MIC90 was 4 μg/mL with a 73.3% susceptibility rate. For ESBL-producing Klebsiella oxytoca (N = 8) the MIC50 and MIC90 were 0.5 and 1 μg/mL, respectively, with a 100% susceptibility rate. Limited agreement (

Original languageEnglish
JournalInternational Journal of Antimicrobial Agents
Volume32
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Nov 2008
Externally publishedYes

Fingerprint

Enterobacteriaceae
Taiwan
Disk Diffusion Antimicrobial Tests
Klebsiella oxytoca
Proteus mirabilis
Klebsiella pneumoniae
Gram-Negative Bacteria
Teaching Hospitals
Escherichia coli
Bacteria
tigecycline
In Vitro Techniques

Keywords

  • Broth microdilution
  • Enterobacteriaceae
  • Etest
  • Extended-spectrum beta-lactamase
  • Taiwan
  • Tigecycline

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae. / Lu, Chin Te; Chuang, Yin Ching; Sun, Wu; Liu, Yung Ching; Cheng, Yu Jen; Lu, Po Liang; Chen, Chih Ming; Hsu, Gwo Jong; Jang, Tsrang Neng; Lee, Chun Ming; Chiang, Ping Cherng; Shi, Zhi Yuan; Wang, Lih Shinn; Kung, Hsiang Chi; Lin, Hsiu Chen; Liao, Chun Hsing; Liu, Jien Wei; Huang, Cheng Hua; Tsao, Shih Ming; Hsueh, Po Ren.

In: International Journal of Antimicrobial Agents, Vol. 32, No. SUPPL. 3, 11.2008.

Research output: Contribution to journalArticle

Lu, CT, Chuang, YC, Sun, W, Liu, YC, Cheng, YJ, Lu, PL, Chen, CM, Hsu, GJ, Jang, TN, Lee, CM, Chiang, PC, Shi, ZY, Wang, LS, Kung, HC, Lin, HC, Liao, CH, Liu, JW, Huang, CH, Tsao, SM & Hsueh, PR 2008, 'Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae', International Journal of Antimicrobial Agents, vol. 32, no. SUPPL. 3. https://doi.org/10.1016/S0924-8579(08)70024-4
Lu, Chin Te ; Chuang, Yin Ching ; Sun, Wu ; Liu, Yung Ching ; Cheng, Yu Jen ; Lu, Po Liang ; Chen, Chih Ming ; Hsu, Gwo Jong ; Jang, Tsrang Neng ; Lee, Chun Ming ; Chiang, Ping Cherng ; Shi, Zhi Yuan ; Wang, Lih Shinn ; Kung, Hsiang Chi ; Lin, Hsiu Chen ; Liao, Chun Hsing ; Liu, Jien Wei ; Huang, Cheng Hua ; Tsao, Shih Ming ; Hsueh, Po Ren. / Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae. In: International Journal of Antimicrobial Agents. 2008 ; Vol. 32, No. SUPPL. 3.
@article{484a6e4f1b514801a983ea37bb81ee88,
title = "Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae",
abstract = "Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria. This study compared the in-vitro activity of tigecycline against clinical isolates of resistant Gram-negative bacteria determined by the broth microdilution and Etest methods. A total of 622 isolates were collected from patients treated at 20 teaching hospitals. Tigecycline had excellent in-vitro activity against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC90 0.5 μg/mL and a 99.6{\%} susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC90 2 μg/mL and a 98.5{\%} susceptibility rate. For ESBL-producing Proteus mirabilis (N = 15) the MIC90 was 4 μg/mL with a 73.3{\%} susceptibility rate. For ESBL-producing Klebsiella oxytoca (N = 8) the MIC50 and MIC90 were 0.5 and 1 μg/mL, respectively, with a 100{\%} susceptibility rate. Limited agreement (",
keywords = "Broth microdilution, Enterobacteriaceae, Etest, Extended-spectrum beta-lactamase, Taiwan, Tigecycline",
author = "Lu, {Chin Te} and Chuang, {Yin Ching} and Wu Sun and Liu, {Yung Ching} and Cheng, {Yu Jen} and Lu, {Po Liang} and Chen, {Chih Ming} and Hsu, {Gwo Jong} and Jang, {Tsrang Neng} and Lee, {Chun Ming} and Chiang, {Ping Cherng} and Shi, {Zhi Yuan} and Wang, {Lih Shinn} and Kung, {Hsiang Chi} and Lin, {Hsiu Chen} and Liao, {Chun Hsing} and Liu, {Jien Wei} and Huang, {Cheng Hua} and Tsao, {Shih Ming} and Hsueh, {Po Ren}",
year = "2008",
month = "11",
doi = "10.1016/S0924-8579(08)70024-4",
language = "English",
volume = "32",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae

AU - Lu, Chin Te

AU - Chuang, Yin Ching

AU - Sun, Wu

AU - Liu, Yung Ching

AU - Cheng, Yu Jen

AU - Lu, Po Liang

AU - Chen, Chih Ming

AU - Hsu, Gwo Jong

AU - Jang, Tsrang Neng

AU - Lee, Chun Ming

AU - Chiang, Ping Cherng

AU - Shi, Zhi Yuan

AU - Wang, Lih Shinn

AU - Kung, Hsiang Chi

AU - Lin, Hsiu Chen

AU - Liao, Chun Hsing

AU - Liu, Jien Wei

AU - Huang, Cheng Hua

AU - Tsao, Shih Ming

AU - Hsueh, Po Ren

PY - 2008/11

Y1 - 2008/11

N2 - Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria. This study compared the in-vitro activity of tigecycline against clinical isolates of resistant Gram-negative bacteria determined by the broth microdilution and Etest methods. A total of 622 isolates were collected from patients treated at 20 teaching hospitals. Tigecycline had excellent in-vitro activity against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC90 0.5 μg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC90 2 μg/mL and a 98.5% susceptibility rate. For ESBL-producing Proteus mirabilis (N = 15) the MIC90 was 4 μg/mL with a 73.3% susceptibility rate. For ESBL-producing Klebsiella oxytoca (N = 8) the MIC50 and MIC90 were 0.5 and 1 μg/mL, respectively, with a 100% susceptibility rate. Limited agreement (

AB - Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria. This study compared the in-vitro activity of tigecycline against clinical isolates of resistant Gram-negative bacteria determined by the broth microdilution and Etest methods. A total of 622 isolates were collected from patients treated at 20 teaching hospitals. Tigecycline had excellent in-vitro activity against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC90 0.5 μg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC90 2 μg/mL and a 98.5% susceptibility rate. For ESBL-producing Proteus mirabilis (N = 15) the MIC90 was 4 μg/mL with a 73.3% susceptibility rate. For ESBL-producing Klebsiella oxytoca (N = 8) the MIC50 and MIC90 were 0.5 and 1 μg/mL, respectively, with a 100% susceptibility rate. Limited agreement (

KW - Broth microdilution

KW - Enterobacteriaceae

KW - Etest

KW - Extended-spectrum beta-lactamase

KW - Taiwan

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=55649108849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649108849&partnerID=8YFLogxK

U2 - 10.1016/S0924-8579(08)70024-4

DO - 10.1016/S0924-8579(08)70024-4

M3 - Article

VL - 32

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - SUPPL. 3

ER -